BMPR2 and pulmonary arterial hypertension: Genetic studies have demonstrated that mutations in bone morphogenic protein receptor type 2 (BMPR2) are present in 80% of hereditable PAH leading to loss of function and reduced downstream signaling [3,4,5,6].